Essential Thrombocythemia

Common Name(s)

Essential Thrombocythemia

Essential thrombocythemia belongs to a group of conditions called myeloproliferative disorders. Myeloproliferative disorders cause platelets, white blood cells and red blood cells to grow abnormally in the bone marrow (the soft tissue inside the hollow part of bones that helps form blood cells). In essential thrombocythemia, the body produces too many platelet cells. The signs and symptoms vary from person to person, with up to two-thirds of patients not having any symptoms when the platelet cell count first increases. Signs and symptoms may include significant increased production of megakaryocyte (a cell in the bone marrow that is responsible for making platelets), enlargement of the spleen (splenomegaly), and bleeding and/or clotting episodes.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Essential Thrombocythemia" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Essential Thrombocythemia" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

http://www.mpnresearchfoundation.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Essential Thrombocythemia" returned 324 free, full-text research articles on human participants. First 3 results:

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.
 

Author(s): Gabriela M Baerlocher, Bart Burington, David S Snyder

Journal: N. Engl. J. Med.. 2015 Dec;373(26):2580.

 

Last Updated: 24 Dec 2015

Go To URL
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
 

Author(s): Gabriela M Baerlocher, Elisabeth Oppliger Leibundgut, Oliver G Ottmann, Gary Spitzer, Olatoyosi Odenike, Michael A McDevitt, Alexander Röth, Michael Daskalakis, Bart Burington, Monic Stuart, David S Snyder

Journal: N. Engl. J. Med.. 2015 Sep;373(10):920-8.

 

Imetelstat, a 13-mer oligonucleotide that is covalently modified with lipid extensions, competitively inhibits telomerase enzymatic activity. It has been shown to inhibit megakaryocytic proliferation in vitro in cells obtained from patients with essential thrombocythemia. In this ...

Last Updated: 3 Sep 2015

Go To URL
JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
 

Author(s): Bo Hyun Kim, Young-Uk Cho, Mi-Hyun Bae, Seongsoo Jang, Eul-Ju Seo, Hyun-Sook Chi, Yunsuk Choi, Dae-Young Kim, Jung-Hee Lee, Je-Hwan Lee, Kyoo-Hyung Lee, Young-Mi Park, Jong-Keuk Lee, Chan-Jeoung Park

Journal: J. Korean Med. Sci.. 2015 Jul;30(7):882-8.

 

Mutations in the calreticulin gene, CALR, have recently been discovered in subsets of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). We investigated Korean patients with ET and PMF to determine the prevalence, and clinical and laboratory correlations ...

Last Updated: 1 Jul 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Essential Thrombocythemia" returned 11 free, full-text review articles on human participants. First 3 results:

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
 

Author(s): Ayalew Tefferi, Tiziano Barbui

Journal: Am. J. Hematol.. 2015 Feb;90(2):162-73.

 

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis. Other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk ...

Last Updated: 23 Jan 2015

Go To URL
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
 

Author(s): Matjaz Sever, Kate J Newberry, Srdan Verstovsek

Journal: Leuk. Lymphoma. 2014 Dec;55(12):2685-90.

 

Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications. However, approximately 20-25% of patients develop resistance or intolerance to HU and must be treated ...

Last Updated: 18 Dec 2014

Go To URL
Personalized management of essential thrombocythemia-application of recent evidence to clinical practice.
 

Author(s): A Tefferi, T Barbui

Journal: Leukemia. 2013 Aug;27(8):1617-20.

 

The World Health Organization (WHO) classification system has recently strengthened the diagnostic criteria for essential thrombocythemia (ET) by lowering the threshold platelet count, underscoring its morphological distinction from early/prefibrotic myelofibrosis (MF) and incorporating ...

Last Updated: 7 Aug 2013

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
 

Status: Not yet recruiting

Condition Summary: MPN; Essential Thrombocythemia

 

Last Updated: 19 Nov 2015

Go to URL
Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
 

Status: Recruiting

Condition Summary: Polycythemia Vera; Essential Thrombocythemia; Myelofibrosis

 

Last Updated: 17 Mar 2016

Go to URL
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
 

Status: Recruiting

Condition Summary: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia

 

Last Updated: 4 Jun 2015

Go to URL